CASI Pharmaceuticals (CASI) received a determination letter from the Hearings Panel of The Nasdaq Stock Market dated February 23, 2026, notifying the Company that the Panel determined to delist the Company’s securities from Nasdaq, due to the Company’s failure to satisfy the continued listing conditions as previously disclosed. As a result, the Company securities will be suspended from trading at the open of business on February 26, 2026, and delisted from Nasdaq after the completion of certain applicable process. The Company does not intend to request a review of such decision.Following the delisting, the Company expects that its ordinary shares will be quoted on the “over the counter” market operated by OTC Markets Group so that a trading market may continue to exist for its ordinary shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI:
- CASI Pharmaceuticals Closes Third Tranche of US$20 Million Convertible Note Financing
- CASI Pharmaceuticals Names New Executive Chairman, Streamlines U.S. Operations Amid Listing Pressure
- CASI Pharmaceuticals Secures China Drug Registration for Thiotepa Ahead of Planned Asset Disposal
- CASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts Sales
- Casi Pharmaceuticals announces NMPA approval of CTA for Phase 1/2 CID-103 study